Study Enrollment


Your details will not be published or shared.

Clinical Trial

Lifestyle Intervention for Healthy Change (LIVE WELL)

The 2016 AACE/ACE guidelines for treating patients with a BMI > 30 outline lifestyle intervention as the first step in management. Lifestyle modification includes a decreased intake of calories, an increase in physical activity as well as motivational or behavioral intervention. The next step adds pharmacotherapy, while surgical management is considered the third option [2]. The Obesity Medicine Association (OMA) also advises a multi-modal approach to treatment but describes dietary changes, physical activity, motivational counseling and use of pharmacotherapy as four equal cornerstones of treatment. For patients that failed to improve with this four-pronged approach, they recommend surgery for patients with a BMI equal to or greater than 40 [6]. The goals of management include improving patient health, quality of life, as well as body weight, and composition [6]. The purpose of this study is to provide a feasible intervention to overweight/obese adults interested in weight loss during physical activity, dietary counseling, and behavior change. If eligible, participants will be randomized into one of two groups. Group 1 (intervention) will receive a Nutrigenomix kit, in adidition to physical activity and behavior change counseling. Group 2 (Control) will not receive the Nutrigenomix kit, but will receive physical activity and behavior counseling. The Nutrigenomix kit will allow for specific nutrition recommendations based on the individual's genetic makeup. The intervention will last a total of 6 months, with a 9-month follow-up.


Eligibility Criteria

  • Inclusion Criteria: Age: 18-40 years BMI status: ?25 If on medications, need to be considered stable for at least 3 months Weight stable (defined as +/- 5 lb) over the past 3 months Commercial Insurance Owns a smartphone device Has a PCP Exclusion Criteria: Pregnant, planning to get pregnant Home Oxygen Immobility Cardiopulmonary disease Moderate to advances systemic disease that precludes the use of all anti-obesity medications

Contact Information

    Madison Kindred

    (706) 731-7924

   mkindred@augusta.edu

RESEARCH. INNOVATION. DISCOVERY.